Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 208.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.98M |
| Shares Out | 31.14M |
| EPS (ttm) | -2.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,656 |
| Open | 6.62 |
| Previous Close | 6.69 |
| Day's Range | 6.51 - 7.18 |
| 52-Week Range | 3.19 - 11.90 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 22.40 (+233.83%) |
| Earnings Date | Nov 13, 2024 |
About ACRV
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ACRV stock is "Strong Buy." The 12-month stock price forecast is $22.4, which is an increase of 233.83% from the latest price.
News
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic canc...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon P...
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon's robust pipeline, incl...
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
WATERTOWN, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with pr...
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onco...
Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data
Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovaria...
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall ...
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on...
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in precl...
Acrivon Therapeutics Announces $130 Million Private Placement Financing
WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on...
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay...
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on...
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
Acrivon's Predictive Precision Proteomics (AP3) platform is a proprietary, broadly applicable, next-generation precision oncology platform at the forefront of the next wave of biology-driven drug disc...
Acrivon Therapeutics to Participate in Two Investor Conferences in September
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...